New Study of Diabetes Drug for COVID-19 Raises Eyebrows

Some question the safety of AstraZeneca's just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19.
Source: WebMD Health - Category: Consumer Health News Source Type: news

Related Links:

Bearing a strong resemblance to the phenotypic and functional remodeling of the immune system that occurs during aging (termed immunesenescence), the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease 2019 (COVID-19), is characterized by an expansion of inflammatory monocytes, functional exhaustion of lymphocytes, dysregulated myeloid responses and the presence of highly activated senescent T cells. Alongside advanced age, male gender and pre-existing co-morbidities [e.g., obesity and type 2 diabetes (T2D)] are emerging as significant risk factors for...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In medical school, I was charged with caring for Ms. R, a 47-year-old woman with type 2 diabetes, hypertension, and rheumatoid arthritis. She had been flagged as a high priority patient through the student-run free clinic (SRFC) and assigned to me for long-term follow-up. This signified seeing her during monthly check-ups, scheduling her appointments with […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions COVID-19 coronavirus Infectious Disease Source Type: blogs
Authors: Munekawa C, Hosomi Y, Hashimoto Y, Okamura T, Takahashi F, Kawano R, Nakajima H, Osaka T, Okada H, Majima S, Senmaru T, Nakanishi N, Ushigome E, Hamaguchi M, Yamazaki M, Fukui M Abstract To investigate the acute effects of the coronavirus disease 2019 (COVID-19) on the lifestyle and metabolic parameters in patients with type 2 diabetes mellites. This cross-sectional and retrospective cohort study induced 203 patients who completed a questionnaire regarding stress levels and lifestyles. Data regarding stress levels, sleep time, exercise, and total diet, snack, and prepared food intake were obtained from the...
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research
An observational, retrospective analysis of 338 patients with type 2 diabetes hospitalized for COVID-19 showed substantially less mortality among sitagliptin recipients compared with those on insulin.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
(Boston Children's Hospital) Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy. Patients given sitagliptin in addition to insulin had a mortality rate of 18 percent as compared with 37 percent in matched patients receiving only insulin. Led by Paolo Fiorina, MD, PhD, of Boston Children's Hospital, the study involved seven Italian hospitals during the first surge of COVID cases last spring.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
The objective of this study is to describe how selected diseases were distributed among adults with confirmed COVID-19 (COVID-19 positive tests) and among those hospitalised for COVID-19 compared to the general population. MATERIAL AND METHOD: We used data from the Norwegian Patient Registry, the Norwegian Registry for Primary Health Care and the Norwegian Surveillance System for Communicable Diseases for adults from the age of 20 and older for the period 1 March 2020-13 May 2020. RESULTS: Of all those who tested positive for COVID-19, 7 632 (94 %) were aged 20 years or older, and 1 025 (13.4 %) of...
Source: Tidsskrift for den Norske Laegeforening - Category: General Medicine Authors: Tags: Tidsskr Nor Laegeforen Source Type: research
Abstract PURPOSE: Coronavirus disease 2019 (COVID-19) has become a topic of concern worldwide; however, the impacts of type 2 diabetes mellitus (T2DM) on disease severity, therapeutic effect, and mortality of patients with COVID-19 are unclear. METHODS: All consecutive patients with COVID-19 admitted to the Renmin Hospital of Wuhan University from January 11 to February 6, 2020, were included in this study. RESULTS: A total of 663 patients with COVID-19 were included, while 67 patients with T2DM accounted for 10.1% of the total. Compared with patients with COVID-19 without T2DM, those with T2DM were olde...
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: J Clin Endocrinol Metab Source Type: research
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a global public health emergency, leading to over a quarter of a million deaths worldwide [1]. Diabetes is a more slowly evolving pandemic, causing 4.2 million deaths worldwide in 2019 [2]. Type 2 diabetes (T2D) disproportionately affects Muslim communities across the world, with many Muslims with diabetes seeking to fast during the month of Ramadan [3]. Fasting during Ramadan is a requirement for all healthy adult Muslims, and entails complete abstention from food and fluids during daylight hours.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
This week, I did something unplanned: I bought a vial of Lilly's " authorized generic " of its brand-name U-100 insulin analog usually branded as Humalog (insulin lispro rDNA origin) at my neighborhood Walgreens for just $68.38. The reason it was unplanned is because I already met the deductible for my insurance plan, so I hadn't expected to deal with this until it resets in January (maybe, I think my new plan covers it without having met the deductible but we'll see). But I had a script I last filled before I met the deductible, and the pharmacy sent a text telling me it was time to refill. In reality, I have in...
Source: Scott's Web Log - Category: Endocrinology Tags: Admelog Drug Channels drug prices GoodRx Humalog insulin Lilly lispro prescriptions rebates Sanofi Walgreens Source Type: blogs
More News: AstraZeneca | COVID-19 | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Health | Study